12:00 AM
 | 
May 18, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tesofensine: Phase I data

Data from the double-blind, placebo- and active-controlled, Canadian Phase I TIPO-5 trial in 44 healthy recreational stimulant users showed that 1-9 mg oral tesofensine met the primary endpoint...

Read the full 118 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >